Black Titan Corp (NASDAQ:BTTC) Sees Significant Decline in Short Interest

Black Titan Corp (NASDAQ:BTTC) was the target of a significant decline in short interest during the month of May. As of May 29th, there was short interest totaling 4,312 shares, a decline of 82.4% from the May 14th total of 24,499 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 33,269 shares, the days-to-cover ratio is presently 0.1 days.

Black Titan Price Performance

NASDAQ:BTTC traded down $0.09 during trading hours on Friday, reaching $0.90. 63,192 shares of the company traded hands, compared to its average volume of 740,834. The firm has a 50-day moving average price of $1.23. The firm has a market capitalization of $9.67 million, a PE ratio of -0.30 and a beta of 1.20. Black Titan has a 1 year low of $0.86 and a 1 year high of $39.00.

Black Titan (NASDAQ:BTTC) last posted its quarterly earnings results on Friday, June 12th. The company reported ($0.22) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BTTC. Renaissance Technologies LLC purchased a new position in Black Titan in the fourth quarter worth about $26,000. HRT Financial LP purchased a new position in Black Titan in the fourth quarter worth about $28,000. Marex Group plc purchased a new position in Black Titan in the fourth quarter worth about $84,000. Finally, Armistice Capital LLC purchased a new position in Black Titan in the fourth quarter worth about $840,000.

Black Titan Company Profile

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.